Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1988 Mar;47(3):190–197. doi: 10.1136/ard.47.3.190

Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy.

M Doherty 1, N Richards 1, J Hornby 1, R Powell 1
PMCID: PMC1003482  PMID: 2833185

Abstract

C3 degradation products (C3dg/d) were estimated in 288 synovial fluid (SF) samples (rheumatoid arthritis (RA) 93, osteoarthritis (OA) 68, chronic pyrophosphate arthropathy 80, acute pseudogout 20, others 27) from knees of 138 patients (bilateral 67, serial sampling on two to six occasions 40). At each aspiration knees were defined as 'active' or 'inactive' by single observer global assessment using six clinical parameters of inflammation. Lack of correlation between paired SF and plasma C3dg/d implied local C3 activation within joints. Raised SF C3d levels were found in active compared with inactive RA joints (mean (range) 51 (15-105) and 6 (0-15) units/ml respectively). Low SF C3dg/d levels were found in OA (mean (range) 0.8 (0-7) units/ml) and chronic pyrophosphate arthropathy (mean (range) 4 (0-16) units/ml), irrespective of clinical activity. In contrast, very high levels (mean (range) 61 (16-126) units/ml) were present in all cases of pseudogout. These differences remained after correction for SF C3 or albumin. This study is the first to show a positive correlation between SF C3dg/d and local inflammation in RA joints. It further suggests that C3 activation is a constant feature of pseudogout but not an accompaniment of inflammation associated with chronic crystal associated synovitis or OA.

Full text

PDF
190

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berkowicz A., Kappelgaard E., Petersen J., Nielsen H., Ingemann-Hansen T., Halkjaer-Kristensen J., Sørensen H. Complement C3c and C3d in plasma and synovial fluid in rheumatoid arthritis. Acta Pathol Microbiol Immunol Scand C. 1983 Dec;91(6):397–402. [PubMed] [Google Scholar]
  2. Brandslund I., Siersted H. C., Svehag S. E., Teisner B. Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma. J Immunol Methods. 1981;44(1):63–71. doi: 10.1016/0022-1759(81)90107-1. [DOI] [PubMed] [Google Scholar]
  3. Byers P. H., Ward P. A., Kellermeyer R. W., Naff G. B. Complement as a mediator of inflammation in acute gouty arthritis. II. Biological activities generated from complement by the interaction of serum complement and sodium urate crystals. J Lab Clin Med. 1973 May;81(5):761–769. [PubMed] [Google Scholar]
  4. Dieppe P. A., Doherty M. The role of particles in the pathogenesis of joint disease. Curr Top Pathol. 1982;71:199–233. doi: 10.1007/978-3-642-68382-4_7. [DOI] [PubMed] [Google Scholar]
  5. Doherty M., Dieppe P. Crystal deposition disease in the elderly. Clin Rheum Dis. 1986 Apr;12(1):97–116. [PubMed] [Google Scholar]
  6. Doherty M., Whicher J. T., Dieppe P. A. Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles. Ann Rheum Dis. 1983 Jun;42(3):285–291. doi: 10.1136/ard.42.3.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. El-Ghobarey A., Whaley K. Alternative pathway complement activation in rheumatoid arthritis. J Rheumatol. 1980 Jul-Aug;7(4):453–460. [PubMed] [Google Scholar]
  8. Hasselbacher P. C3 activation by monosodium urate monohydrate and other crystalline material. Arthritis Rheum. 1979 Jun;22(6):571–578. doi: 10.1002/art.1780220603. [DOI] [PubMed] [Google Scholar]
  9. Hasselbacher P. Immunoelectrophoretic assay for synovial fluid C3 with correction for synovial fluid globulin. Arthritis Rheum. 1979 Mar;22(3):243–250. doi: 10.1002/art.1780220306. [DOI] [PubMed] [Google Scholar]
  10. Hedberg H., Lundh B., Laurell A. B. Studies of the third component of complement in synovial fluid from arthritic patients. II. Conversion and its relation to total complement. Clin Exp Immunol. 1970 May;6(5):707–712. [PMC free article] [PubMed] [Google Scholar]
  11. Hunder G. G., McDuffie F. C., Clark R. J. Consumption of C3 via the classical and alternative complement pathways by sera and synovial fluids from patients with rheumatoid arthritis. J Clin Lab Immunol. 1979 Nov;2(4):269–273. [PubMed] [Google Scholar]
  12. Hunder G. G., McDuffie F. C., Mullen B. J. Activation of complement components C3 and factor B in synovial fluids. J Lab Clin Med. 1977 Jan;89(1):160–171. [PubMed] [Google Scholar]
  13. Inman R. D., Harpel P. C. C1 inactivator-C1s complexes in inflammatory joint disease. Clin Exp Immunol. 1983 Sep;53(3):521–528. [PMC free article] [PubMed] [Google Scholar]
  14. Kerr M. A. The human complement system: assembly of the classical pathway C3 convertase. Biochem J. 1980 Jul 1;189(1):173–181. doi: 10.1042/bj1890173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kim H. J., McCarty D. J., Kozin F., Koethe S. Clinical significance of synovial fluid total hemolytic complement activity. J Rheumatol. 1980 Mar-Apr;7(2):143–152. [PubMed] [Google Scholar]
  16. Krauledat P. B., Krapf F. E., Manger B., Kalden J. R. Evaluation of plasma C3d and immune complex determinations in the assessment of disease activity of patients with rheumatoid arthritis, systemic lupus erythematosus, and spondylitis ancylopoetica. Rheumatol Int. 1985;5(3):97–101. doi: 10.1007/BF00541327. [DOI] [PubMed] [Google Scholar]
  17. McCarty D. J., Kozin F. An overview of cellular and molecular mechanisms in cyrstal-induced inflammation. Arthritis Rheum. 1975 Nov-Dec;18(6 Suppl):757–764. doi: 10.1002/art.1780180720. [DOI] [PubMed] [Google Scholar]
  18. Mollnes T. E., Lea T., Mellbye O. J., Pahle J., Grand O., Harboe M. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum. 1986 Jun;29(6):715–721. doi: 10.1002/art.1780290603. [DOI] [PubMed] [Google Scholar]
  19. Mollnes T. E., Paus A. Complement activation in synovial fluid and tissue from patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1986 Nov;29(11):1359–1364. doi: 10.1002/art.1780291108. [DOI] [PubMed] [Google Scholar]
  20. Moxley G., Ruddy S. Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 1985 Oct;28(10):1089–1095. doi: 10.1002/art.1780281003. [DOI] [PubMed] [Google Scholar]
  21. Nydegger U. E., Zubler R. H., Gabay R., Joliat G., Karagevrekis C. H., Lambert P. H., Miescher P. A. Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity. J Clin Invest. 1977 May;59(5):862–868. doi: 10.1172/JCI108708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nürnberger W., Bhakdi S. Plasma C3d/C3 quotient as a parameter for in vivo complement activation. J Immunol Methods. 1984 Nov 16;74(1):87–91. doi: 10.1016/0022-1759(84)90370-3. [DOI] [PubMed] [Google Scholar]
  23. Ochi T., Yonemasu K., Ono K. Immunochemical quantitation of complement components of Clq and C3 in sera and synovial fluids of patients with bone and joint diseases. Ann Rheum Dis. 1980 Jun;39(3):235–240. doi: 10.1136/ard.39.3.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Perrin L. H., Nydegger U. E., Zubler R. H., Lambert P. H., Miescher P. A. Correlation between levels of breakdown products of C3, C4, and properdin factor B in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 1977 Mar;20(2):647–652. doi: 10.1002/art.1780200202. [DOI] [PubMed] [Google Scholar]
  25. Petz L. D., Powers R., Fries J. R., Cooper N. R., Holman H. R. The in vivo metabolism of the third component of complement in systemic lupus erythematosus. Arthritis Rheum. 1977 Sep-Oct;20(7):1304–1313. doi: 10.1002/art.1780200702. [DOI] [PubMed] [Google Scholar]
  26. Powell R. J., Leyland A. M., Pound J. D., Bossingham D. H. An improved assay for IgG rheumatoid factor: its value in the diagnosis of rheumatoid arthritis. J Rheumatol. 1985 Jun;12(3):427–431. [PubMed] [Google Scholar]
  27. Reyes P. A., Maluf J. G., Curd J. G., Vaughan J. H. Association of rheumatoid factor with complement activation in rheumatoid arthritis and other diseases. Clin Exp Immunol. 1983 Aug;53(2):391–396. [PMC free article] [PubMed] [Google Scholar]
  28. Ruddy S., Colten H. R. Rheumatoid arthritis. Biosynthesis of complement proteins by synovial tissues. N Engl J Med. 1974 Jun 6;290(23):1284–1288. doi: 10.1056/NEJM197406062902304. [DOI] [PubMed] [Google Scholar]
  29. Ruddy S., Fearon D. T., Austen K. F. Depressed synovial fluid levels of properdin and properdin factor B in patients with rheumatoid arthritis. Arthritis Rheum. 1975 Jul-Aug;18(4):289–295. doi: 10.1002/art.1780180401. [DOI] [PubMed] [Google Scholar]
  30. Schmid F. R., Roitt I. M., Rocha M. J. Complement fixation by a two-component antibody system: immunoglobulin G and immunoglobulin M anti-globulin (rheumatoid factor). Parodoxical effect related to immunoglobulin G concentration. J Exp Med. 1970 Oct 1;132(4):673–693. doi: 10.1084/jem.132.4.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sheppeard H., Lea D. J., Ward D. J. Synovial fluid total hemolytic complement activity in rheumatic diseases - a reappraisal. J Rheumatol. 1981 May-Jun;8(3):390–397. [PubMed] [Google Scholar]
  32. Sliwinski A. J., Zvaifler N. J. Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus. Clin Exp Immunol. 1972 May;11(1):21–29. [PMC free article] [PubMed] [Google Scholar]
  33. Tanimoto K., Cooper N. R., Johnson J. S., Vaughan J. H. Complement fixation by rheumatoid factor. J Clin Invest. 1975 Mar;55(3):437–445. doi: 10.1172/JCI107949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Townes A. S., Sowa J. M. Complement in synovial fluid. Johns Hopkins Med J. 1970 Jul;127(1):23–37. [PubMed] [Google Scholar]
  35. VAUGHAN J. H., BAYLES T. B., FAVOUR C. B. Serum complement in rheumatoid arthritis. Am J Med Sci. 1951 Aug;222(2):186–192. [PubMed] [Google Scholar]
  36. Zvaifler N. J. Breakdown products of C 3 in human synovial fluids. J Clin Invest. 1969 Aug;48(8):1532–1542. doi: 10.1172/JCI106119. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES